Perspective for prophylaxis and treatment of cervical cancer: An immunological approach

International Reviews of Immunology

Volumn 31, Issue 1, 2012, Pages 3-21

  Jenkins, Marjorie ^a,b   Chiriva Internati, Maurizio ^a,b   Mirandola, Leonardo ^a,b   Tonroy, Catherine ^a   Tedjarati, Sean S ^b   Davis, Nicole ^a   D'Cunha, Nicholas ^a   Tijani, Lukman ^a   Hardwick, Fred ^a   Nguyen, Diane ^a   Kast, W Martin ^c,d   Cobos, Everardo ^a,b  

^a TEXAS TECH UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Cancer vaccines; Gynecologic oncology; HPV; Immunotherapy; Tumor prevention

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CALRETICULIN; DENDRITIC CELL VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; NAKED DNA; NEUTRALIZING ANTIBODY; PLACEBO; PLATINUM; PROTEIN E6; PROTEIN E7; TUMOR ANTIGEN; TUMOR MARKER; VIRUS VECTOR; WART VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; COLPOSCOPY; CONDYLOMA ACUMINATUM; DIPHTHERIA; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYSTERECTOMY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PATHOPHYSIOLOGY; PELVIS LYMPHADENECTOMY; PERTUSSIS; POLIOMYELITIS; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TETANUS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VAGINA CANCER; VIRAL GENE THERAPY; VULVA CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 84856120727     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2011.637254     Document Type: Review

References (96)

1. Brinkman JA,Caffrey AS,Muderspach LI, et al.The impact of antiHPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinicalmanagement. Eur JGynaecol Oncol. 2005; 26:129-142. (Pubitemid 40546518)
2. Kim JJ, Goldie SJ.Health and economic implications of HPV vaccination in the United States. N Engl JMed. 2008; 359:821-832.
3. Kahn JA.HPV vaccination for the prevention of cervical intraepithelial neoplasia.NEngl JMed. 2009; 361:271-278.
4. Gershenson DM. Gynecologic Cancer: Controversies in Management. Philadelphia, PA: Elserver; 2004.
5. Hoskins WJ. Principles and Practive of Gynecologic Oncology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
6. Beller U, Abu-Rustum NR. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol. 2009; 113:550-552.
7. Franco EL, Schlecht NF, Saslow D.The epidemiology of cervical cancer. Cancer J. 2003; 9:348-359. (Pubitemid 44403488)
8. Insinga RP,Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005; 23:1107-1122. (Pubitemid 41633402)
9. Huh WK.Human papillomavirus infection: a concise review of natural history.ObstetGynecol. 2009; 114:139-143.
10. WhitesideMA, Siegel EM, Unger ER. Human papillomavirus and molecular considerations for cancerrisk. Cancer. 2008; 113:2981-2994.
11. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18:1606-1613. (Pubitemid 30220538)
12. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999; 73:177-183. (Pubitemid 29215728)
13. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl JMed. 1999; 340:1137-1143. (Pubitemid 29177872)
14. WhitneyCW, SauseW, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervixwith negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17:1339-1348. (Pubitemid 29220838)
15. Rose PG, Bundy BN,Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl JMed. 1999; 340:1144-1153. (Pubitemid 29177873)
16. Roman LD, Felix JC,Muderspach LI, et al. Risk of residual invasive disease in women with microinvasive squamous cancer in a conization specimen. Obstet Gynecol. 1997; 90:759-764. (Pubitemid 27449729)
17. Creasman WT, Zaino RJ, Major FJ, et al. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1998; 178:62-65. (Pubitemid 28302796)
18. Burnett AF, Roman LD, O'Meara AT, et al. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol. 2003; 88:419-423. (Pubitemid 36331999)
19. Landoni F,Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350:535-540. (Pubitemid 27348428)
20. Long HJ 3rd,Monk BJ,HuangHQ, et al. Clinical results and quality of life analysis for theMVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 100:537-543. (Pubitemid 43246869)
21. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 23:4626-4633. (Pubitemid 46224065)
22. Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer. 2007; 111:1-14. (Pubitemid 46281079)
23. Holladay EB, Logan S, Arnold J, et al.Acomparison of the clinical utility of p16(INK4a)immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer. 2006; 108:451-461. (Pubitemid 46076964)
24. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008; 337:a1754.
25. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;19:K29-K41.
26. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007; 370:890-907. (Pubitemid 47371147)
27. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl JMed. 2003; 348:489-490. (Pubitemid 36159883)
28. Rowhani-Rahbar A,Mao C, Hughes JP, et al. Longer termefficacy of a prophylacticmonovalent human papillomavirus type 16 vaccine. Vaccine. 2009; 27:5612-5619.
29. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98:765-774. (Pubitemid 43983300)
30. Hildesheim A, Herrero R. Human papillomavirus vaccine should be given before sexual debut for maximumbenefit. J Infect Dis. 2007 Nov 15;196(10):1431-1432. Epub 2007 Oct 31. (Pubitemid 351411975)
31. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine. 2009; 27:581-587.
32. Munoz N,Manalastas R, Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373:1949-1957.
33. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenicHPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374:301-314.
34. Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374:1975-1985.
35. Koulova A, Tsui J, Irwin K, et al. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 2008; 26:6529-6541.
36. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl JMed. 2007; 356:1908-1910. (Pubitemid 46740300)
37. Garcia-Sicilia J, Schwarz TF, Carmona A, et al.Immunogenicity and safety of human papillomavirus- 16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanusacellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health. 2010; 46:142-151.
38. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl JMed. 2007; 356:1928-1943. (Pubitemid 46740303)
39. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl JMed. 2007; 356:1915-1927.
40. Wheeler CM, Kjaer SK, Sigurdsson K, et al.The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009; 199:936-944.
41. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199:926-935.
42. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102:325-339.
43. Food and Drug Administration. Product approval-prescribing information [package insert] Gardasil R- [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck and Co, Inc: Food and Drug Administration. 2009. Available from www.fda.gov/BiologicsBloodVaccines/ Vaccines/ApprovedProducts/UCM094042.
44. Merck USA. Highlights of prescribing information: GARDASIL R- [human papillomavirus quadrivalent (Types 6, 11, 16, and 18) vaccine, Recombinant] 2008. Available from www.merck.com/product/usa/pi circulars/g/Gardasil R- pi.pdf.
45. Human papillomavirus vaccines. WHO position paper.Wkly Epidemiol Rec. 2009; 84:118-131.
46. Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J TranslMed. 2010; 8:105.
47. Olsson SE, Villa LL, Costa RL, et al. Induction of immunememory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25:4931-4939. (Pubitemid 46843434)
48. AultKA.Effect of prophylactichuman papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369:1861-1868. (Pubitemid 46829356)
49. Policy statement: Recommended childhood and adolescent immunization schedules-United States, 2010. Pediatrics. 2010; 125:195-196.
50. Friedman LS, Kahn J,Middleman AB, et al. Human papillomavirus (HPV) vaccine: a position statement of the Society for AdolescentMedicine. J Adolesc Health. 2006 Oct;39(4):620. (Pubitemid 44375051)
51. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007; 40:564-571. (Pubitemid 46771257)
52. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infectionwithhumanpapillomavirus types 16 and 18 inyoungwomen:an interimanalysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369:2161-2170. (Pubitemid 46977438)
53. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br JCancer. 2006; 95:1459-1466. (Pubitemid 44863348)
54. McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs. 2011; 71:465-488.
55. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007; 25:4324-4333. (Pubitemid 46635934)
56. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007; 97:1322-1328. (Pubitemid 350035812)
57. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine. 2008; 26:6258-6265.
58. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008; 122:247-259. (Pubitemid 350234709)
59. Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenicmouse model for HPV-16 transformed tumors. Vaccine. 2008; 26:5315-5320.
60. Bermudez-Humaran LG, Cortes-PerezNG, Le Loir Y, et al. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. JMedMicrobiol. 2004; 53:427-433. (Pubitemid 38586510)
61. Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cell-surface display of E7 antigen fromhuman papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cellwall anchor from lactobacilli. J Drug Target. 2005; 13:89-98. (Pubitemid 40542541)
62. Peters C, Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine. 2003; 21:1187-1194. (Pubitemid 36139948)
63. Maciag PC, Radulovic S, Rothman J.Thefirst clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009; 27:3975-3983.
64. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002; 8:3676-3685. (Pubitemid 35424757)
65. Baez-Astua A,Herraez-Hernandez E,GarbiN, et al. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7- specific antibody and cytotoxic T-cell responses. J Virol. 2005; 79:12807-12817. (Pubitemid 41433200)
66. Santin AD, Bellone S, Roman JJ, et al.Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr PharmDes. 2005; 11:3485-3500. (Pubitemid 41300755)
67. Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006; 100:469-478. (Pubitemid 43246861)
68. Tsen SW, Paik AH, Hung CF, et al. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6:227-239. (Pubitemid 46607458)
69. Hung CF,Wu TC. Improving DNA vaccine potency viamodification of professional antigen presenting cells. Curr OpinMol Ther. 2003; 5:20-24.
70. Lu D,Hoory T,Monie A, et al. Treatmentwith demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009; 27:4363-4369.
71. Smahel M, Polakova I, Pokorna D, et al. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int J Oncol. 2008; 33:93-101.
72. Massa S, Simeone P, Muller A, et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther. 2008; 19:354-364. (Pubitemid 351591427)
73. Kim TW,Hung CF, BoydD, et al. EnhancingDNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol. 2003; 171:2970-2976. (Pubitemid 37093519)
74. Kim TW, Lee JH, He L, et al. Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 2005; 65:309-316. (Pubitemid 40070823)
75. Sheets EE, Urban RG, Crum CP, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.Am J Obstet Gynecol. 2003; 188:916-926. (Pubitemid 36530038)
76. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16 +cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009; 15:361-367.
77. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulatesHLA class-I,HLA class-II and ICAM-1 molecules. Int JCancer. 1997; 71:630-637. (Pubitemid 27239375)
78. Gorelik L, FlavellRA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. NatMed. 2001; 7:1118-1122. (Pubitemid 33010019)
79. Munn DH,Mellor AL. IDO and tolerance to tumors. TrendsMolMed. 2004; 10:15-18 (Pubitemid 38165324)
80. Rubinstein N, AlvarezM, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell. 2004; 5:241-251. (Pubitemid 38402116)
81. Goldberg MV,Maris CH, Hipkiss EL, et al. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007; 110:186-192. (Pubitemid 47026834)
82. Kim R, Emi M, Tanabe K, et al. Tumor-driven evolution of immunosuppressive networks duringmalignant progression. Cancer Res. 2006; 66:5527-5536. (Pubitemid 43927099)
83. Kanodia S, Da Silva DM, Karamanukyan T, et al. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus type 16 E7 induces significant tumor regression. Cancer Res. 2010; 70:3955-3964.
84. Fahey LM, Raff AB, Da Silva DM, et al. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009; 182:2919-2928.
85. Karanam B, Jagu S, Huh WK, et al. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009; 87:287-299.
86. Jagu S, Karanam B, Gambhira R, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009; 101:782-792.
87. Melief CJ. Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus. Cancer J. 2011; 17:300-301.
88. KreimerAR, CliffordGM, Boyle P, et al.Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14:467-475. (Pubitemid 40270113)
89. Ryan DP,Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000; 12:345-352.
90. Chin-Hong PV, Husnik M, Cranston RD, et al. Anal human papillomavirus infection is associated with HIV acquisition in men who have sex withmen. AIDS. 2009; 23:1135-1142.
91. Winer RL,Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl JMed. 2006; 354:2645-2654.
92. HernandezBY, Wilkens LR, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008; 14:888-894. (Pubitemid 351838596)
93. Baldwin SB,Wallace DR, PapenfussMR, et al. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis. 2004; 31:601-607. (Pubitemid 39281832)
94. Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009; 27:141-150.
95. Bleeker MC, Hogewoning CJ, Van Den Brule AJ, et al. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol. 2002; 47:351-357.
96. Giuliano A, Palefsky J. The efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. In: Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress, November 12-15, 2008. Nice, France: Acropolis. Abstract SS 19-7a.